Martingale Asset Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10,853
Closed -$293K 848
2025
Q2
$293K Sell
10,853
-7,600
-41% -$220K 0.01% 708
2025
Q1
$547K Sell
18,453
-5,603
-23% -$214K 0.01% 584
2024
Q4
$953K Sell
24,056
-2,498
-9% -$94.6K 0.02% 485
2024
Q3
$904K Sell
26,554
-3,551
-12% -$99.9K 0.02% 485
2024
Q2
$652K Buy
30,105
+6,504
+28% +$137K 0.01% 545
2024
Q1
$523K Buy
23,601
+9,428
+67% +$230K 0.01% 607
2023
Q4
$390K Sell
14,173
-98
-0.7% -$2.37K 0.01% 658
2023
Q3
$319K Sell
14,271
-6
-0% -$154 0.01% 678
2023
Q2
$364K Buy
14,277
+3,002
+27% +$72.8K 0.01% 665
2023
Q1
$251K Buy
11,275
+1,112
+11% +$26.9K ﹤0.01% 735
2022
Q4
$241K Buy
+10,163
New +$236K ﹤0.01% 760

Other funds holding VCYT

Martingale Asset Management's VCYT Position: Q3 2025 in Review

Martingale Asset Management sold out of Veracyte (VCYT) in Q3 2025, closing a stake of 10,853 shares — an estimated $293K sold.

Martingale Asset Management first reported a position in VCYT in Q4 2022 and held it in 11 quarters. The position peaked at $953K in Q4 2024. 298 funds tracked by Wall St. Rank hold VCYT as of Q3 2025.

  • Martingale Asset Management reported no remaining Veracyte position as of Q3 2025 after selling out during the quarter.
  • Martingale Asset Management sold 10,853 Veracyte shares in Q3 2025, an estimated $293K.
  • Martingale Asset Management first reported a position in Veracyte in Q4 2022 and held it in 11 quarters.
  • Martingale Asset Management's Veracyte position peaked at $953K in Q4 2024.
  • 298 funds tracked by Wall St. Rank held Veracyte as of Q3 2025.

Based on Martingale Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.